IRIS
BUTTITTA, Fiamma
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.595
EU - Europa 3.757
AS - Asia 3.721
SA - Sud America 486
Continente sconosciuto - Info sul continente non disponibili 257
AF - Africa 63
OC - Oceania 10
Totale 14.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.337
SG - Singapore 1.543
CN - Cina 1.032
IT - Italia 589
UA - Ucraina 541
IE - Irlanda 483
GB - Regno Unito 469
SE - Svezia 402
RU - Federazione Russa 398
BR - Brasile 387
TR - Turchia 324
VN - Vietnam 318
FR - Francia 310
DE - Germania 253
IN - India 164
CA - Canada 127
FI - Finlandia 117
HK - Hong Kong 62
BD - Bangladesh 43
MX - Messico 41
PL - Polonia 41
AR - Argentina 37
IQ - Iraq 34
JP - Giappone 31
KR - Corea 27
CZ - Repubblica Ceca 26
NL - Olanda 24
BE - Belgio 20
ES - Italia 20
ID - Indonesia 20
TW - Taiwan 19
IL - Israele 17
PK - Pakistan 17
CR - Costa Rica 16
EC - Ecuador 16
ZA - Sudafrica 15
AT - Austria 13
CO - Colombia 13
JM - Giamaica 13
SA - Arabia Saudita 13
VE - Venezuela 12
LT - Lituania 11
NI - Nicaragua 11
SC - Seychelles 11
TT - Trinidad e Tobago 11
MA - Marocco 9
PY - Paraguay 9
CL - Cile 8
EE - Estonia 8
IR - Iran 8
MY - Malesia 8
PR - Porto Rico 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
EU - Europa 7
GT - Guatemala 7
SV - El Salvador 7
BA - Bosnia-Erzegovina 6
CH - Svizzera 6
HN - Honduras 6
LB - Libano 6
CW - ???statistics.table.value.countryCode.CW??? 5
ET - Etiopia 5
GP - Guadalupe 5
JO - Giordania 5
KE - Kenya 5
TN - Tunisia 4
AZ - Azerbaigian 3
DZ - Algeria 3
EG - Egitto 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PH - Filippine 3
SN - Senegal 3
UG - Uganda 3
AM - Armenia 2
DK - Danimarca 2
MK - Macedonia 2
NP - Nepal 2
PA - Panama 2
RO - Romania 2
RS - Serbia 2
TH - Thailandia 2
UY - Uruguay 2
UZ - Uzbekistan 2
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
DM - Dominica 1
GA - Gabon 1
GD - Grenada 1
GR - Grecia 1
HU - Ungheria 1
KG - Kirghizistan 1
KZ - Kazakistan 1
Totale 14.633
Salva come PNG Salva come JPEG
Città #
Singapore 1.157
San Jose 691
Chandler 654
Jacksonville 612
Dublin 471
Ashburn 372
Beijing 270
Southend 264
Council Bluffs 245
Princeton 232
Dallas 206
Izmir 188
Nanjing 186
Santa Clara 164
Los Angeles 162
New York 109
Cambridge 101
Dearborn 101
Ho Chi Minh City 95
The Dalles 90
Wilmington 90
Buffalo 83
Tongling 82
Altamura 71
Boardman 70
Ann Arbor 67
Chieti 63
Munich 63
Hanoi 62
North Bergen 62
Nanchang 57
Hong Kong 54
Pescara 53
Shenyang 49
Milan 41
Moscow 38
Phoenix 37
São Paulo 36
Kimball 34
Atlanta 33
Rome 33
Warsaw 33
Brooklyn 30
Montreal 30
Tianjin 29
Denver 28
Chicago 27
Hangzhou 27
Woodbridge 27
Hebei 26
Seoul 26
Chennai 25
Orem 24
Redondo Beach 24
Tokyo 24
Kunming 23
Stockholm 22
Toronto 22
Washington 22
Grevenbroich 21
Boston 20
Houston 19
Augusta 18
London 17
Mexico City 17
Brussels 16
Columbus 16
Norwalk 16
Poplar 16
Baghdad 15
Da Nang 15
Jiaxing 15
Helsinki 14
Jinan 14
San José 14
San Mateo 14
Taichung 14
Biên Hòa 13
Brno 13
Ningbo 13
Belo Horizonte 12
Collecorvino 12
Frankfurt am Main 12
Rio de Janeiro 12
Claxton 11
New Delhi 11
Orange 11
Turku 11
Changsha 10
Charlotte 10
Kingston 10
Managua 10
Nuremberg 10
Haiphong 9
Hefei 9
Johannesburg 9
Manchester 9
Dong Ket 8
Latina 8
Miami 8
Totale 8.549
Salva come PNG Salva come JPEG
Nome #
Assessing EGFR mutations. 273
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 239
A unique microRNA signature associated with plaque instability in humans. 224
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 222
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 204
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 199
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 197
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 175
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 170
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 170
A unique microRNA signature associated with ischemic stroke in humans 169
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 168
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 166
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 162
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 162
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 161
AKT1(E17K) in human solid tumours 161
Mutational profile of GNAQQ209 in human tumors. 161
POLE exonuclease domain mutations in endometrial carcinoma: a case report 157
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 157
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 156
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 155
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 155
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 154
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 153
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 152
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 150
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 148
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 144
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 144
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 144
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 142
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 142
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 141
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 140
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 138
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 137
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 137
Survivin gene expression in early-stage non-small cell lung cancer. 136
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 136
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 136
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 135
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 135
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 135
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 134
Association between cigarette smoking and FHIT gene alterations in lung cancer. 133
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 133
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 131
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 130
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 129
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 129
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 129
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 127
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 127
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 126
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 125
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 125
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 124
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 124
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 123
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 123
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 123
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 123
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 121
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 119
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 119
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 118
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 118
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 117
Hypertension modulates miR-145 expression in human atherosclerotic plaques 117
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 117
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 115
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 115
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 112
Nucleotide and deduced amino acid sequences of tumor gene INT6. 111
Detection of gene mutations on cytological specimens: clinical implications 110
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 108
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 108
BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients 108
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report 107
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 107
Real-world data on NGS diagnostics: A survey from the Italian Society of Pathology (SIAPeC) NGS Network 107
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 106
Predictive markers in lung cancer: A few hints for the practicing pathologist 105
Identification of microRNAs 758 and 33b as potential modulators ofABCA1 expression in human atherosclerotic plaques 105
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 104
Prostatic cancer: molecular bases. 103
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 102
Evaluation of FHIT gene alterations in ovarian cancer 101
p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. 100
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. 100
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. 97
p53 mutations and histological type of invasive breast carcinoma. 96
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients 95
Stabilita’ del dna in campioni citologici conservati in fase liquida 92
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. 91
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. 91
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 89
Reduced expression of INT-6/eIF3-p48 in human tumors. 89
Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. 89
Totale 13.469
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.421
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022439 0 0 0 0 31 23 13 38 50 33 84 167
2022/20231.709 144 216 70 212 193 345 96 105 233 12 46 37
2023/2024762 68 24 44 23 50 229 153 33 4 27 2 105
2024/20252.249 114 451 376 49 56 74 81 88 235 103 246 376
2025/20264.256 351 245 376 563 478 283 626 280 424 332 231 67
2026/20271.506 74 211 245 660 316 0 0 0 0 0 0 0
Totale 14.889